Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DDI Study of EDP-305 with Fluconazole and Quinidine
NCT03610945Phase 1Completed
- Sponsor
- Enanta Pharmaceuticals
- Start
- Jul 2018
- Primary completion
- Aug 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of EDP-305 in Nonalcoholic steatohepatitis (NASH) (2 arms), sponsored by Enanta Pharmaceuticals. Primary endpoints: Maximum Plasma Concentration (Cmax) of EDP-305 up to 19 days and Area Under the Plasma Concentration-Time Curve (AUC) of EDP-305 up to 19 days. Started Jul 2018; status: completed.
02
Drugs
EDP-305
03
Conditions
Nonalcoholic steatohepatitis (NASH)
Beyond the preview
Go deeper on NCT03610945.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03610945.